Coronary Artery Bypass Graft Market

The global Coronary Artery Bypass Graft Market is valued at USD 13.5 Billion in 2023 and is projected to reach a value of USD 30.59 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 9.5% between 2024 and 2032. The market is driven by rising global prevalence of coronary heart disease. According to WHO estimates, cardiovascular diseases are the top cause of death worldwide, claiming 17.9 million lives annually.

Key Highlights

• Based on the Method, the Off-pump category accounted for significant market share of 52.6% in 2023
• In 2023, by Surgical Procedure, Single CABG Surgery dominated the market with significant market share of 33.3%
• Based on End-use, Hospitals dominated the market with market share of 54.1% in 2023
• North America dominated the market with 48.3% market share in 2023
• Asia Pacific region is anticipated to grow at the highest CAGR of 15.6% during the forecast period
• The growing rates of chronic conditions like diabetes and hypertension also drive the expansion of the Coronary Artery Bypass Graft market

Method Overview

​The Method segment is divided into Off-pump, On-pump, Minimally Invasive Direct. The Off-pump segment held the dominant share in 2023, accounting for significant market share of 52.6%.

Off-pump segment’s growth is driven by the advantages of the method, including shorter hospital stays, smaller incisions, and quicker recovery times. Additionally, it lowers the risk of post-surgical complications such as infections, arrhythmias, and inflammation. Off-pump procedures also provide safer options for patients with conditions like cirrhosis, chronic lung disease, and kidney issues. These benefits collectively contribute to the expanding market demand for this method.

Surgical Procedure Overview

The Surgical Procedure segment is divided into Single CABG Surgery, Double CABG Surgery, Triple CABG Surgery, Quadruple CABG Surgery. In 2023, the Single CABG Surgery segment held largest share of 33.3% in the Coronary Artery Bypass Graft market.

Coronary artery bypass grafting (CABG) is one of the most commonly performed major procedures, particularly for cases involving blockages in one or more cardiac arteries. Among the heart’s three coronary arteries, the left anterior descending artery (LAD) stands out as the most critical. A blockage or narrowing in the LAD is more dangerous compared to obstructions in the other arteries and can lead to a life-threatening heart attack. In many instances, bypass surgery is the most effective treatment for a blocked LAD, and the widespread use of this procedure for LAD blockages drives the growth of the single CABG segment.

Regional Overview

In 2023, the North America captured 48.3% of the revenue share.

North America Coronary Artery Bypass Graft market is driven by widespread occurrence of cardiovascular diseases in the region, along with technological advancements that provide both off-pump and on-pump bypass procedures for patients. Additionally, numerous private institutions and the Centers for Medicare & Medicaid Services (CMS) offer reimbursement for medical devices and surgeries. These combined factors are fueling market expansion in the region.

U.S. Coronary Artery Bypass Graft market, valued at USD 5.1 Billion in 2023 to USD 11.83 Billion in 2032, is anticipated to grow at a CAGR of 9.8% from 2024 to 2032. The country’s substantial and aging population has led to a higher incidence of cardiovascular diseases, frequently requiring coronary artery bypass graft (CABG) procedures. Furthermore, the United Nations projects that the elderly population will double to 2.1 billion by 2050. Additionally, the U.S. benefits from a well-developed healthcare system, cutting-edge medical technologies, and a strong reimbursement structure, making CABG surgeries more accessible across the nation. This demographic is at higher risk for cardiovascular diseases due to the gradual buildup of fat deposits in the arteries.

Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period, driven by factors such as the increasing elderly population in India and China. According to WHO, by 2040, approximately 402 million people in China will be over 60 years old. These countries also experience a high mortality rate from coronary heart disease (CHD), which further fuels market expansion.

China held the largest market share in the Asia Pacific region. The combination of a large population and a growing incidence of cardiovascular diseases has created a significant demand for coronary artery bypass graft (CABG) procedures. Moreover, China's rapidly growing economy has resulted in increased healthcare spending and infrastructure development, improving access to advanced treatments like CABG surgeries.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

• Growing adoption of minimally invasive surgical techniques: Surgeons are increasingly using less invasive techniques, which result in smaller incisions, faster recovery times, and fewer complications for patients
• Increased use of robotic-assisted surgeries: Robotic-assisted technology allows for greater precision and control during surgery, leading to better outcomes
• Development of bioengineered and polymer-based grafts: New graft materials, such as bioengineered or polymer-based grafts, are being developed to improve durability and the long-term success of CABG surgeries

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing Prevalence of Cardiovascular Diseases (CVDs)

A major cause of death globally, cardiovascular diseases are becoming more common, mostly as a result of sedentary lifestyles, poor diets, and rising rates of obesity and diabetes. The need for coronary artery bypass graft (CABG) procedures has increased due to the notable rise in the prevalence of coronary artery disease. When treating severe coronary artery disease, which is frequently characterized by blockages in the arteries supplying blood to the heart, CABG is still one of the most successful treatments available.

High Cost Associated with Surgery Procedures

CABG is a complicated process that need for sophisticated equipment, lengthy hospital stays, and specific surgical experience, making it one of the most expensive cardiovascular procedures. In developed regions, healthcare systems may cover some of the costs, but in developing countries with limited insurance coverage or public healthcare infrastructure, many patients find the cost prohibitive. Access to CABG surgery is restricts by this financial burden, especially in low- and middle-income nations. The high cost may discourage patients from choosing more expensive options like angioplasty or stenting, even in developed markets, which would further limit market expansion.

Advancements in Graft Materials present a significant opportunity for the market

Traditionally, veins or arteries from the patient's body have been used for bypass grafts, but these can sometimes fail over time, leading to complications or the need for additional surgeries. However, developments in synthetic and bioengineered graft materials are transforming the industry. In order to improve integration with the body's tissues, lower the chance of rejection, and increase durability, new graft materials are being developed. Furthermore, studies on tissue-engineered materials and polymer-based grafts are promising in terms of enhancing patient outcomes and CABG procedure success rates over time.

Competitive Landscape

The Coronary Artery Bypass Graft market is highly competitive, with several key players actively driving innovation and expanding their product offerings. Large corporations with a wide range of cardiovascular goods and cutting-edge technologies, such as Johnson & Johnson, Terumo Corporation, Edwards Lifesciences, and Medtronic, are pushing the market. Strategic alliances, investments, and acquisitions—like Medtronic's acquisition of Affera, Inc. and Grand Pharmaceutical's investment in Xeltis—shape the competitive environment. In order to improve patient outcomes, businesses are concentrating on creating minimally invasive procedures, polymer-based restorative devices, and other cutting-edge treatments, which is fueling competition in the CABG industry.

The key players in the global Coronary Artery Bypass Graft market include - Terumo Corporation, Guidant Group, Medtronic plc, MAQUET Holding B.V. & Co.KG, Novadaq Technologies Inc., KARL STORZ GmbH & Co. KG, Genesee Biomedical Inc., Sorin Group, Edwards Lifesciences Corporation among others.

Recent Market Developments

Kimal PLC Partners with Marizyme, Inc. to Advance DuraGraft for Ischemia-Reperfusion Injury Prevention

• In February 2023, Kimal PLC entered into a strategic partnership with Marizyme, Inc. to advance their flagship product, DuraGraft, which is designed to prevent ischemia-reperfusion injury—a significant factor in vein graft disease

Grand Pharmaceutical Group Invests $16.5 Million in Xeltis for Advanced Cardiovascular Devices

• In August 2022, Grand Pharmaceutical Group from China invested $16.5 million in Xeltis, a Dutch medical device company renowned for its innovative clinical solutions. This investment is intended to support Xeltis in developing polymer-based restorative devices for cardiovascular treatments, including heart valves and small-diameter arteries used in Coronary Artery Bypass Graft (CABG) procedures

Medtronic Acquires Affera, Inc. to Expand Cardiovascular Product Portfolio

• In August 2022, Medtronic finalized its acquisition of Affera, Inc., a move anticipated to broaden the company's cardiovascular product offerings